Dr. Kittai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1425 Madison Avenue
New York, NY 10029
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2016 - 2019
George Washington UniversityChief Residency, Internal Medicine, 2015 - 2016- George Washington UniversityResidency, Internal Medicine, 2012 - 2015
Tel Aviv University SacklerClass of 2012
Certifications & Licensure
NY State Medical License 2023 - 2025
OH State Medical License 2019 - 2024
OR State Medical License 2016 - 2021
DC State Medical License 2015 - 2016
VA State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia Start of enrollment: 2022 Sep 13
Roles: Contact, Principal Investigator
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Start of enrollment: 2023 Jul 28
Roles: Sponsor-Investigator, Contact, Principal Investigator
Publications & Presentations
PubMed
- Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL.Jacob D Soumerai, Jacqueline Claudia Barrientos, Inhye E Ahn, Catherine C Coombs, Douglas E Gladstone
Blood Advances. 2024-11-19 - Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse la...Rossana Di Staso, Beatrice Casadei, Frederick L Locke, Michael Jain, Timothy J Voorhees
Blood Cancer Journal. 2024-11-07 - 1 citationsAtrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.John Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, Mussammat Ferdousi, Onaopepo Kola-Kehinde
Leukemia. 2024-10-01
Abstracts/Posters
- Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo StudiesAdam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective AnalysisAdam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center AnalysisAdam S. Kittai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Community Cancer Practices Implement Venetoclax Protocols for CLL, but Gaps RemainDecember 8th, 2024- A Matching-Adjusted Indirect Comparison (MAIC) of the Efficacy and Safety of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJuly 30th, 2024
- Efficacy of New Agents, CAR-T Insights Among EHA 2024 Highlights in CLLJuly 12th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
